GlassScriptPhysician profile
Candelaria Mcelhinney
NPI 1922363274
$6,628.17
in general payments reported to CMS, 2019-2025
31 companies · $2,118 in 2025
The $2,118 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,253 · 2022: $875 · 2023: $741 · 2024: $1,642 · 2025: $2,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,251 · Long Term Medical Supply Or Device Loan: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,250.92 |
| Long Term Medical Supply Or Device Loan | $2,249.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,083.65 | 2021-2025 | |
| Seagen INC. | $459.98 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $369.63 | 2022-2025 | Tagrisso, Enhertu, Calquence |
| Abbvie INC. | $199.33 | 2024-2025 | |
| Gilead Sciences, INC. | $162.75 | 2022-2025 | Trodelvy |
| Myriad Genetic Laboratories, INC. | $137.86 | 2023 | Myrisk |
| Pfizer INC. | $129.58 | 2025 | |
| Janssen Biotech, INC. | $125.66 | 2024-2025 | Rybrevant, Carvykti, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $104.48 | 2024-2025 | Fruzaqla, Alunbrig |
| Genzyme Corporation | $100.76 | 2023-2025 | |
| Daiichi Sankyo INC. | $89.68 | 2023-2025 | Enhertu, Datroway |
| Lilly USA, LLC | $89.31 | 2021-2025 | Jaypirca, Verzenio |
| Sanofi-Aventis U.S. LLC | $66.99 | 2022 | |
| Genentech USA, INC. | $65.54 | 2024-2025 | Tecentriq, Perjeta, Kadcyla |
| Incyte Corporation | $59.90 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $42.23 | 2025 | |
| Astellas Pharma US INC | $36.59 | 2025 | Xtandi, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $30.30 | 2025 | |
| Pharmacosmos Therapeutics INC. | $28.97 | 2025 | Monoferric |
| Celgene Corporation | $28.67 | 2023 | Reblozyl |
| Pharmaessentia USA Corporation | $26.44 | 2023 | Besremi |
| Merck Sharp & Dohme LLC | $23.37 | 2024 | Lynparza, Keytruda |
| Tactile Systems Technology INC | $22.97 | 2025 | Flexitouch Plus, Nimbl |
| Exelixis INC. | $22.93 | 2025 | Cabometyx |
| Agios Pharmaceuticals, INC. | $21.74 | 2025 | Pyrukynd |
| Adc Therapeutics America, INC. | $19.42 | 2025 | |
| Glaxosmithkline, LLC. | $18.94 | 2024 | Ojjaara |
| Tempus Ai, INC | $16.72 | 2025 | Xt Cdx |
| Beone Medicines USA, INC. | $16.01 | 2025 | Tevimbra |
| Adaptive Biotechnologies Corporation | $13.93 | 2025 | Clonoseq |
| Sumitomo Pharma America, INC. | $13.84 | 2023 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candelaria Mcelhinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.